{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gout/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ea99909d-2b07-4fbe-a619-9d2e71f674ac --><h2>Changes</h2><!-- end field ea99909d-2b07-4fbe-a619-9d2e71f674ac -->","summary":null,"htmlStringContent":"<!-- begin item 841ac16c-0a51-4051-88af-b4212dddddcf --><!-- begin field 6114cfdd-b298-4ca9-beee-c4b9035a35cb --><p><strong>November 2017 to February 2018</strong> — reviewed. A literature search was conducted in October 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The recommendations on medical management of acute gout and prevention of gout have been amended and are in line with national guidance. Minor structural changes have been made to the topic. </p><!-- end field 6114cfdd-b298-4ca9-beee-c4b9035a35cb --><!-- end item 841ac16c-0a51-4051-88af-b4212dddddcf -->","topic":{"id":"7ec7842e-cb8a-5712-bb55-65480a391cb5","topicId":"b578fac4-ab4b-4d7b-9df9-2136b4d90e75","topicName":"Gout","slug":"gout","lastRevised":"Last revised in February 2018","chapters":[{"id":"2e71494e-f9a3-5368-8903-3d2121329748","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738bb44e-1a50-5bc5-8df4-83ac66475493","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69338c48-0d43-5ae0-9591-5ef289880366","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes"},{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update"}]},{"id":"5de6e4cf-e0c8-56e2-a357-3d063b324cd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"86664a1d-e3e5-58c9-957b-56affa17f103","slug":"goals","fullItemName":"Goals"},{"id":"39593d8e-f904-5b99-80e9-e619caf1ec37","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca59f248-a0b2-5f6c-bfcf-2333dc94f1d9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"57ca55f4-826e-5832-85a7-dd89f3486be2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"621c09b7-b5e8-593b-aeb2-fc4a86b884c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b39fbed2-7c0d-5440-a769-bab311a7b4d2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"362edeaf-2f90-506d-b203-f5dbbbfb5835","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a8de4056-6ec0-59ff-911b-561bf7fdb32d","slug":"definition","fullItemName":"Definition"},{"id":"45a8241d-2a2d-5a48-a6d6-2b5ebe02ec27","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"92d229bf-8656-5cfa-aecc-9c069389300f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"79d3b1c2-8d49-55be-99af-41b37c84d582","slug":"complications","fullItemName":"Complications"},{"id":"27dd91cd-92bb-5c2d-8fe8-a184bffce6e7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ddea0193-0c14-53db-8e1e-2e71f514988e","slug":"assessment","fullItemName":"Assessment"},{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations"},{"id":"42a5d4a2-b908-5027-8fb8-f5f336db4c7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5a915955-8e0e-54ae-a1cc-f5875d84d2a2","fullItemName":"Management","slug":"management","subChapters":[{"id":"8a8b4d2a-4efb-5bef-9780-70dc540d41bd","slug":"acute-gout","fullItemName":"Scenario: Acute gout"},{"id":"98793041-11dd-5159-a376-82f5440ee713","slug":"preventing-gout","fullItemName":"Scenario: Preventing gout"}]},{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e7cfef3f-4ab1-5d17-8300-30e91a70eb96","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine"},{"id":"60f4beab-f8fc-50e5-8ed9-5073dd8533ec","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol"},{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat"},{"id":"ff3edf82-1b21-591c-a8a5-a3b40e7386a5","slug":"paracetamol","fullItemName":"Paracetamol"}]},{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"71a86333-9110-5847-a2c2-eabf7903c269","slug":"application-of-an-ice-pack","fullItemName":"Application of an ice pack"},{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2921e0f0-467f-5231-87d0-9fed766653ee","slug":"oral-colchicine","fullItemName":"Oral colchicine"},{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"409d2bc0-16d2-5104-8857-eeb5db2a1ecc","slug":"dietary-measures","fullItemName":"Dietary measures"},{"id":"08526f72-ca5a-50db-94b6-3380365360fd","slug":"colchicine-to-prevent-recurrent-gout","fullItemName":"Colchicine to prevent recurrent gout"},{"id":"a53517a7-6d7e-5d2f-886d-e2a3f1bc27b1","slug":"urate-lowering-drugs-in-prevention","fullItemName":"Urate-lowering drugs in prevention"}]},{"id":"f83d98a9-6ce1-50d4-92ad-dd354662a444","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"568c43a6-b0d8-546e-84d2-45781ce305cc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5b7cac11-c21d-59fc-83d9-bf16d0d3ab0b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0e4d0013-b7bc-5179-ac55-8104dec2762c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d75afbe0-7c3d-504e-b369-e56eac297bad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"45249d1d-8c92-5402-b4f3-108a8a39d94f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"44f1a411-2cf4-55e8-b5e8-266cd568655e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"69338c48-0d43-5ae0-9591-5ef289880366","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"f20590d4-7fee-52c7-8aa5-267e4ef842f5","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field cc739789-841e-446a-90ce-6772f2b01024 --><h3>Previous changes</h3><!-- end field cc739789-841e-446a-90ce-6772f2b01024 -->","summary":null,"htmlStringContent":"<!-- begin item 2131c1cb-6d5f-460e-9573-38db1be8e788 --><!-- begin field 99dba067-fa8f-4518-9de6-4c658d84ff9b --><p><strong>January 2018 </strong>— minor update. Infomation on screening before starting treated with allopurinol updated as per the manufacturer's Summary of Product Characteristics.</p><p><strong>January 2017</strong> — minor update. Information that blood creatine phosphokinase increase is a rare adverse reaction of Adenuric120 mg film-coated tablets in line with a change to the manufacturer's Summary of Product Characteristics.</p><p><strong>December 2016</strong> — minor update. Information that colchicine is contraindicated in people taking ritonavir has been added to this topic, in line with a change to the manufacturer's Summary of Product Characteristics.</p><p><strong>July 2016 </strong>— minor update. The recommended maximum alcohol intake has been updated in line with the Alcohol Guidelines Review published by the Department of Health (2016).</p><p><strong>April 2015 </strong>—<strong> </strong>minor update. A link to the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> has been inserted.</p><p><strong>February 2015 </strong>— minor update. Probenecid has been discontinued. References to probenecid have been removed from the topic.</p><p><strong>February 2014 </strong>— minor update to the prescribing information section for allopurinol.</p><p><strong>July 2013 </strong>— minor update. The text has been updated to reflect recent guidance from the MRHA regarding diclofenac.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2013 </strong>— minor update. Black triangle status removed from febuxostat, and advice from the Medicines and Healthcare products Regulatory Agency regarding hypersensitivity reactions of febuxostat has been inserted.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>August 2012 </strong>— reviewed. A literature search was conducted in August 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>February 2012 </strong>— minor update. Updated to include the recommendation from the House of Commons Science and Technology Committee that people should have at least two alcohol-free days per week. Issued in March 2012.</p><p><strong>July 2011 </strong>— minor update. Update of febuxostat to include postmarketing reports of skin rashes and hypersensitivity reactions highlighted in the updated Summary of Product Characteristics. Issued in September 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2010 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>June 2010 </strong>— updated to include the option of using febuxostat for the management of chronic gout for people who are intolerant of allopurinol, or for whom allopurinol is contraindicated. This is in line with National Institute for Health and Clinical Excellence technology appraisal guidance <em>Febuxostat for the management of hyperuricaemia in people with gout</em>. In addition, in people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line NSAIDs. Issued in July 2010.</p><p><strong>December 2009 </strong>— minor update. Triamcinolone acetonide (Kenalog<sup>®</sup>) pre-filled syringes have been discontinued. Prescription replaced with triamcinolone acetonide 40 mg/1 mL vials. Issued in December 2009.</p><p><strong>July to November 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The recommendations have been revised to be in-line with the British Society for Rheumatology and the British Health Professionals guidelines for the management of gout published in 2007. The dose and duration of recommended drug treatments have been updated to be in-line with current practice, in particular, for oral prednisolone.</p><p><strong>November 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently reminded prescribers that colchicine has a narrow therapeutic window and is extremely toxic in overdose</p><p><strong>June 2009 </strong>— minor update. The intra-articular corticosteroid prescriptions have been updated. Issued in June 2009.</p><p><strong>January 2009 </strong>— minor typographical correction. Issued in February 2009.</p><p><strong>July 2005 </strong>— update to text discussing nonsteroidal anti-inflammatory drugs (NSAIDs) in the <em>Prescribing information </em>section. Issued in July 2005.</p><p><strong>January 2005 </strong>— reviewed. Validated in March 2005 and issued in April 2005.</p><p><strong>August 2001 </strong>— reviewed. Validated in November 2001 and issued in April 2002.</p><p><strong>April 1999 </strong>— written. Validated in July 1999 and issued in August 1999.</p><!-- end field 99dba067-fa8f-4518-9de6-4c658d84ff9b --><!-- end item 2131c1cb-6d5f-460e-9573-38db1be8e788 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}